SAM
ATXI

Shikiar Asset Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Shikiar Asset Management’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-167
Closed -$9K – 78
2023
Q3 		$9K Sell
167
-166
-50% -$11.7K ﹤0.01% 77
2023
Q2 		$29K Buy
333
+200
+150% +$16.5K 0.01% 78
2023
Q1 		$12K Buy
+133
New +$12.3K ﹤0.01% 79

Other funds holding ATXI

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Shikiar Asset Management's ATXI Position: Q4 2023 in Review

Shikiar Asset Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2023, closing a stake of 167 shares — an estimated $9K sold.

Shikiar Asset Management first reported a position in ATXI in Q1 2023 and held it in 3 quarters. The position peaked at $29K in Q2 2023. 14 funds tracked by Wall St. Rank hold ATXI as of Q4 2023.

  • Shikiar Asset Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Shikiar Asset Management sold 167 Avenue Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $9K.
  • Shikiar Asset Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q1 2023 and held it in 3 quarters.
  • Shikiar Asset Management's Avenue Therapeutics, Inc. Common Stock position peaked at $29K in Q2 2023.
  • 14 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Shikiar Asset Management's 13F filing for Q4 2023, filed 1 Feb 2024.